Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is collaborating with Premier Consulting to prepare a pre-investigational new drug (“IND”) package and meeting request with the United States Food and Drug Administration (FDA) for SPC-26, the company’s novel topical formulation of ketamine for the treatment of fibromyalgia. The company is planning to pursue a 505(b)(2) regulatory pathway for novel topical formulation of ketamine. According to the company, Premier Consulting will assist with the development of SILO’s nonclinical, clinical, clinical pharmacology, and biopharmaceutics strategy and program to be proposed to the FDA. Silo is planning to submit the pre-IND meeting request for collaborative discussions with the FDA in anticipation of the filing a clinical IND package. “We are confident that our highly constructive preclinical work on SP-26 will offer strong support for our pre-IND package as we seek to advance our time-released ketamine delivery system into the clinic,” said Silo Pharma CEO Eric Weisblum in the press release. “We intend to pursue the 505(b)(2) regulatory pathway and have engaged Premier Consulting as a true strategic partner to pave the way for productive discussions and alignment with the FDA.”
To view the full press release, visit https://ibn.fm/RoAOh
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health-care industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.